



AFIRM
Armed Forces Institute of Regenerative Medicine



McGowan Institute for Regenerative Medicine
University of Pittsburgh and UPMC



OUR SCIENCE FOR THEIR HEALING

Mission

ARMED FORCES INSTITUTE OF REGENERATIVE MEDICINE IS DEDICATED TO REPAIRING BATTLEFIELD INJURIES THROUGH THE USE OF REGENERATIVE MEDICINE THERAPIES.

Vision

REGENERATIVE MEDICINE IS A PROMISING FIELD THAT HAS ALREADY ACHIEVED EARLY SUCCESS IN THE REGENERATION OF SEVERAL TISSUES AND ORGANS FOR REPAIR OR REPLACEMENT. REGENERATIVE MEDICINE ENCOMPASSES MANY NOVEL APPROACHES FOR THE TREATMENT OF DAMAGED TISSUES AND ORGANS BY USING THERAPIES THAT PROMPT THE BODY TO AUTONOMOUSLY REGENERATE, AND BY USING THE PATIENT'S OWN CELLS ON BIODEGRADABLE BIOMATERIALS FOR THE CREATION OF ENGINEERED TISSUES OR ORGANS FOR THERAPY.



"OUR GOAL IS TO USE OUR POSITION AS THE INTERNATIONAL LEADER IN DEVELOPING RESTORATIVE THERAPIES FOR BATTLEFIELD TRAUMA TO IMPROVE THE OUTCOMES FOR OUR WOUNDED."

- DR. ALAN RUSSELL

THE MCGOWAN INSTITUTE FOR REGENERATIVE MEDICINE HAS BEEN SELECTED AS CO-LEADER

of a national \$85 million program to use the science of regenerative medicine to develop new treatments for wounded soldiers. The new federally funded institute – the Armed Forces Institute of Regenerative Medicine (AFIRM) – will be made up of the U.S. Army Institute of Surgical Research and a national consortium of institutions led, in part, by the McGowan Institute.

"Researchers from the University's McGowan Institute for Regenerative Medicine are known throughout the world for their cutting-edge research that is providing real hope for dramatic advances in human health" said Pitt Chancellor Mark A. Nordenberg. "The Institute has fast become one of the nation's leaders in developing organ and tissue technologies as viable clinical therapies, and through its involvement in AFIRM, the Institute will continue to progress in this vitally important area."

AFIRM will be co-directed by Alan J. Russell, Ph.D., director of the McGowan Institute for Regenerative Medicine. The massive project will be dedicated to repairing battlefield injuries through the use of regenerative medicine, science that takes advantage of the body's natural healing powers to restore or replace damaged tissue and organs.

Therapies developed by AFIRM also will benefit people in the civilian population with burns or severe trauma due to illness or injury.

"Our goal is to use our position as the international leader in developing restorative therapies for battlefield trauma to improve the outcomes for our wounded," said Dr. Russell, who is the founding president of the Tissue Engineering and Regenerative Medicine International Society (TERMIS). "Our ability to provide these treatments is in part due to our team's long experience in this field and our broad pipeline of technologies."

FIVE AREAS OF FOCUS:

Compartment Syndrome – therapies to repair injuries related to burn and blast incidents

Functional Limb and Digit – reconstruction, regeneration or transplantation

Craniofacial Reconstruction – restoration of craniofacial structures

Wound Healing – reduction of scar tissue and inflammation

Burn Repair – regeneration or replacement of skin



AFIRM'S BENEFIT TO WESTERN PENNSYLVANIA AND THE COMMONWEALTH OF PENNSYLVANIA


AFIRM's support, as a federally financed research and development presence at the McGowan Institute (MIRM) will help support MIRM's efforts to commercialize regenerative medicine technologies and accelerate the translation of research discoveries into clinical implementation for civilian patient benefit. There are tremendous economic benefits to this emerging industry that will result in many new companies for this region.

FOR MORE INFORMATION:

Visit our web site at: www.mcgowan.pitt.edu/AFIRM
Or call us at 412-235-5200.

OUR PARTNERS

AFIRM will be made up of two multi-institutional consortia, one lead by the McGowan Institute for Regenerative Medicine, University of Pittsburgh and the Wake Forest Institute for Regenerative Medicine, Wake Forest University and one lead by Rutgers University and the Cleveland Clinic.



McGowan Institute for Regenerative Medicine
University of Pittsburgh and UPMC